Document:

HTML Editor

EXHIBIT 4.6

DESCRIPTION OF REGISTRANT'S SECURITIES

 

Common Stock

 

Our authorized capital stock includes 100,000,000 shares of common stock, par value $0.001 per share. As of March 31, 2022 there were of 68,120,003 shares of common stock issued and outstanding, and 33,333 shares of common stock held in the treasury. The following description of the rights of the common stock do not apply to the treasury shares.

 

The holders of outstanding common stock are entitled to receive dividends out of assets legally available therefor at such times and in such amounts as the Board of Directors may from time to time determine. Each stockholder is entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. Directors are elected by plurality vote. Therefore, the holders of a majority of the common stock voted can elect all of the directors then standing for election. The common stock is not entitled to preemptive rights and is not subject to conversion. If we are liquidated or dissolved or our business is otherwise wound up, the holders of common stock would be entitled to share ratably in the distribution of all of our assets remaining available for distribution after satisfaction of all our liabilities and the payment of the liquidation preference of any outstanding preferred shares.

 

Authorized but Unissued Common Stock

 

The Delaware General Corporation Law does not require stockholder approval for any issuance of authorized shares, except in certain limited circumstances. However, the listing requirements of the NYSE American, which apply for so long as our common stock is listed on the NYSE American, require stockholder approval of certain issuances (other than a public offering) equal to or exceeding 20% of the then outstanding voting power or then outstanding number of shares of common stock, as well as for certain issuances of stock in compensatory transactions. We will not need to obtain stockholder approval for the issuance of the common stock to be sold in this offering. These additional shares may be used for a variety of corporate purposes, including future public offerings, to raise additional capital or to facilitate acquisitions. One of the effects of the existence of unissued and unreserved shares of common stock may be to enable our Board of Directors to sell shares to persons friendly to current management, for such consideration, in form and amount, as is acceptable to the Board, which issuance could render more difficult or discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise, and thereby protect the continuity of our management and possibly deprive stockholders of opportunities to sell their common stock at prices higher than prevailing market prices.

 

Anti-Takeover Provisions

 

Delaware Law

 

We are subject to Section 203 of the DGCL. This provision generally prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years following the date the stockholder became an interested stockholder, unless:

 

• prior to such date, the board of directors approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;

 

• upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of voting shares outstanding those shares owned by persons who are directors and also officers and by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or

 

• on or subsequent to such date, the business combination is approved by the board of directors and authorized at an annual meeting or special meeting of stockholders and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder.

 

Section 203 defines a business combination to include:

 

• any merger or consolidation involving the corporation and the interested stockholder;

 

• any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;

 

• subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;

 

• any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or

 

• the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.

 

In general, Section 203 defines an “interested stockholder” as any entity or person beneficially owning 15% or more of the outstanding voting stock of a corporation, or an affiliate or associate of the corporation and was the owner of 15% or more of the outstanding voting stock of a corporation at any time within three years prior to the time of determination of interested stockholder status; and any entity or person affiliated with or controlling or controlled by such entity or person.

 

These statutory provisions could delay or frustrate the removal of incumbent directors or a change in control of us. They could also discourage, impede, or prevent a merger, tender offer, or proxy contest, even if such event would be favorable to the interests of stockholders.

 

Certificate of Incorporation and Bylaw Provisions

 

Our certificate of incorporation and bylaws contain provisions that could have the effect of discouraging potential acquisition proposals or making a tender offer or delaying or preventing a change in control, including changes a stockholder might consider favorable. In particular, the certificate of incorporation and bylaws, as applicable, among other things:

 

• provide our board of directors with the ability to alter its bylaws without stockholder approval; and

 

• provide that vacancies on our board of directors may be filled by a majority of directors in office, although less than a quorum.

 

Such provisions may have the effect of discouraging a third-party from acquiring us, even if doing so would be beneficial to our stockholders. These provisions are intended to enhance the likelihood of continuity and stability in the composition of our board of directors and in the policies formulated by them, and to discourage some types of transactions that may involve an actual or threatened change in control of us. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage some tactics that may be used in proxy fights. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure our Company outweigh the disadvantages of discouraging such proposals because, among other things, negotiation of such proposals could result in an improvement of their terms. However, these provisions could have the effect of discouraging others from making tender offers for our shares that could result from actual or rumored takeover attempts. These provisions also may have the effect of preventing changes in our management.

 

Our certificate of incorporation provides that no director is personally liable to us or our stockholders for monetary damages for any breach of fiduciary duty by such director as a director. Nonetheless, a director is liable to the extent provided by applicable law, (i) for breach of the director’s duty of loyalty to us or our stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) pursuant to Section 174 of the DGCL (relating to unlawful payment of dividend or unlawful stock purchase or redemption) or (iv) for any transaction from which the director derived an improper personal benefit. If the DGCL is amended to authorize the further elimination or limitation of the liability of directors, then the liability of one of our directors, in addition to the limitation on personal liability provided in our certificate of incorporation, will be limited to the fullest extent permitted by the amended DGCL. No amendment to or repeal of the relevant article of our certificate of incorporation will apply to or have any effect on the liability or alleged liability of any of our directors for or with respect to any acts or omissions of such director occurring prior to such amendment.

 

Our certificate of incorporation furthermore states that we shall indemnify, to the fullest extent permitted by Section 145 of the DGCL, as amended from time to time, each person that such section grants us the power to indemnify. Insofar as indemnification for liability under the Securities Act may be permitted for our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

 

Dividends

 

We have not declared or paid any cash dividends on our common stock, and we do not anticipate declaring or paying cash dividends for the foreseeable future. We are not subject to any legal restrictions respecting the payment of dividends, except that we may not pay dividends if the payment would render us insolvent. Any future determination as to the payment of cash dividends on our common stock will be at our board of directors’ discretion and will depend on our financial condition, operating results, capital requirements and other factors that our board of directors considers to be relevant. Currently, the board of directors does not intend to pay any cash dividends, but retain all funds for working capital.

 

Transfer Agent and Registrar

 

The transfer agent and registrar for our common stock and warrants is Continental Stock Transfer & Trust Company.ex_348600.htm

Exhibit 10.21

 

BUY AND SELL AGREEMENT

 

THIS AGREEMENT (the “Agreement”), is entered into as of November 22, 2021, (the “Effective Date”) by and between WAND DENTAL, INC., (“Wand Dental”), a corporation organized and existing under the laws of the State of Delaware and having its principal place of business at 425 Eagle Rock Avenue, Roseland, NJ 07068, USA and Michelle Zhang dba Solee Science & Technology USA (“Buyer”), a corporation organized and existing under the laws of the country of USA and having its principal office at 233 Mt. Airy Road, Basking Ridge, NJ 07920

 

 

 

WITNESSETH

 

WHEREAS, Wand Dental desires to sell the Products as defined below through Buyer

 

WHEREAS, the Buyer desires to buy Products defined below; and

 

WHEREAS, the parties desire to enter into this Agreement governing their relationship; and

 

NOW THEREFORE, in consideration of the premises and of the mutual covenants and agreements hereinafter set forth, the parties hereto agree as follows:

 

 

	
			1.

				
			Appointment and Territory.

			

 

	 	
			A.

				
			Wand Dental hereby agrees to sell to Buyer the Wand ® System Instruments, associated handpieces, and spare parts (the “Products”)

			

 

	 	
			B.

				
			The geographical area, hereinafter referred to as the “Territory”, in which the Buyer shall have sales rights is the country of China and is only allowed to sell the Products to Anhui Mashida Technology Co., Ltd. China.

			

 

 

	
			2.

				
			Term.

			

 

	 	
			A.

				
			The term of this Agreement shall be for the period commencing on the Effective Date and ending on November 30, 2022.

			

 

	 	
			B.

				
			Buyer shall buy the following minimum quantities during the first year of this Agreement:

			

 

STA Instruments : 600 Handpieces: 4 containers

 

 

 

 

 

	
			3.

				
			Prices to the Buyer.

			

 

	 	
			A.

				
			Wand Dental agrees to sell the Products to the Buyer at the prices specified below, except as otherwise noted herein. All prices to the Distributor are quoted in United States Dollars.

			

STA Instruments: $800 per instrument E.X.W. Wand Dental’s Warehouse, U.S.A (Incoterms 2020).

Handpieces; Container price $359,964 based on 356,400 units per container at $1,01 per unit. The units will be delivered from Tianjing factory to Anhui warehouse at the address: Room A509, Kechuang Center, No. 399, Meishan Road, Maanshan Economic and Technological Development Zone, Anhui China.

 

	 	
			B.

				
			Wand Dental reserves the right at any time during the Term of this Agreement to change its prices within ninety (90) days written notice to the Buyer.

			

 

 

	
			4.

				
			Orders and Shipments.

			

 

	 	
			A.

				
			All orders for Products are subject to acceptance by Wand Dental. A formal numbered purchase order from the Seller is required before the order is considered firm.

			

 

	 	
			B.

				
			Wand Dental shall not be liable to the Seller or the Seller’s customers for any delays in executing orders by reasons of acts of government, strikes, transportation condition, labor or material shortages, embargoes, fires, wars and/or civil disturbances, adverse weather conditions, or other causes beyond the control of Wand Dental.

			

 

 

	
			5.

				
			Warranty.

			

 

Warranty Terms

 

Products are supplied for use in accord with approved label instructions only. Wand Dental warrants the Products are free from defects in material and manufacture and conform to Wand Dental’s specifications at the time of shipment. Purchaser shall at all times store and transport the Products in accord with all storage or transport conditions set by Wand Dental. Subject to verification by Wand Dental, if any Product fails to conform to the specifications or any defect in material or manufacture appears: 1) for Products which are within two (2) years from the date of installation with proper documentation of date of installation; or without proper documentation two (2) years from the original shipment date and 2) for related Consumable Products within 30 days from the date of shipment, Wand Dental’s entire liability and Purchaser’s exclusive remedy shall be, at Wand Dental’s sole discretion, the repair or replacement of the defective Products.

 

2

 

 

Limitations to Warranty

 

Maintenance and repairs during the Warranty term shall be the responsibility of Purchaser. This warranty does not cover any damage to Products or injury to an operator or patient due to misuse, alteration of the product, improper site selection, and maintenance or operation by Purchaser or any others which is contrary to recommended instructions and design parameters for the Products.  This warranty does not cover damage or defects resulting from repair of the Products by anyone other than a Wand Dental representative. Certain items which are refurbished or otherwise reconditioned are also excluded from the terms of this warranty. This warranty does not cover any damage due to accidents, vandalism, fire, flood, other environmental factors or any other Force Majeure. If you have questions regarding warranty coverage, please contact Wand Dental Purchaser Service.

 

THIS WARRANTY IS MADE IN LIEU OF ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE; ANY IMPLIED WARRANTY ARISING OUT OF A COURSE OF DEALING OR OF PERFORMANCE, CUSTOM OR USAGE OF TRADE; OR ANY IMPLIED WARRANTY AGAINST PATENT INFRINGEMENT.

 

 

UNDER NO CIRCUMSTANCES SHALL WAND DENTAL BE LIABLE FOR DAMAGES OF ANY KIND, INCLUDING WITHOUT LIMITATION, DIRECT, INDIRECT, INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES (INCLUDING, BUT NOT LIMITED TO, LOSS OF PROFITS, REVENUE OR BUSINESS) RESULTING FROM OR IN ANY WAY RELATED TO THE PRODUCTS. These limitations apply regardless of whether such damages are sought based on breach of contract, negligence, strict liability in tort, or any other legal theory. The liability of Wand Dental relating to any order by Purchaser shall in no event exceed the total amount of the payments received by Wand Dental relating to such order. Without regard to any applicable statute of limitations, Purchaser agrees that any legal action related to any order must be commenced within ninety (90) days of the purchase date.

 

	
			6.

				
			Expenses of Distributor’s Business.

			

 

The Buyer shall be responsible for any and all expenses, charges, fees, and taxes that may be levied or imposed by any and all authorities within the Territory or elsewhere upon, or by reason of, the carrying on of its activities under this Agreement.

 

	
			7.

				
			Payment.

			

 

	 	
			A.

				
			Payment terms for the STA instruments are: 25% deposit is required with the PO 90 days before shipping. The balance is due when Wand Dental confirms the readiness to ship. Prices are payable in US Dollars and are exclusive of freight, insurance, VAT, and/or applicable sales taxes (Incoterms 2020). Unless otherwise specified in writing, payment for the order will be made to Wand Dental by electronic bank transfer (BACS Payments) in US Dollars. Credit terms, if any, are at Wand Dental's sole discretion and may be altered at any time.

			

Payment terms for the handpieces are: 25% deposit is required with the PO 90 days before shipping. The balance is due 90 days after, upon receipt of the Handpieces at Anhui warehouse.

 

	 	
			B.

				
			Guarantee of Payments

			

 

Both Michelle Zhang and Solee Science & Technology U.S.A., Ltd will be responsible and guarantee for all payments on purchases.

 

3

 

 

 

	
			8.

				
			Termination

			

 

	 	
			A.

				
			Either party shall be able to terminate this Agreement with Thirty (90) days written notice to the other party at any time during the Term.

			

All payments will be immediately due on all outstanding balances.

 

 

	
			9.

				
			Governing Language and Law.

			

 

This Agreement shall be governed by the laws of the State of New York, without regards to its conflicts of laws principles, and the parties hereto irrevocably agree to submit to the jurisdiction and venue of the courts located in the Southern District of New York.

 

 

	
			10.

				
			Counterparts.

			

 

This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together will constitute one and the same instrument.

 

In Witness Whereof, the parties have duly executed this Agreement in duplicate originals on the day and year set forth below:

 

	Wand Dental , Inc.	Solee Science & technology USA
	 	 
	By:         _________________________	By:         _________________________
	 	 
	Name:         _________________________	Name: _________________________
	 	 
	Title:         _________________________	Title:         _________________________
	 	 
	Date:         _________________________ 	Date: _________________________

                                    

 

 

Michelle Zhang                                    

 

 

By:         _________________________         

 

Name:         _________________________         

 

Title:         _________________________         

 

Date:         _________________________         

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]